Catalyst Trusteeship Acquires 47.95% Share Pledge in Bliss GVS Pharma
Bliss GVS Pharma Ltd 路 Acquisition/ Disposal of Shares 路 06 Oct 2026, 3:56 pm
Catalyst Trusteeship Acquires 47.95% Share Pledge in Bliss GVS Pharma Catalyst Trusteeship Limited, acting as debenture trustee on behalf of debenture holders, acquired an encumbrance via pledge over 5,09,84,595 equity shares of Bliss GVS Pharma Ltd on 30th Sep'26. The transaction represents 47.95% of the company's total voting capital and 46.77% of its total diluted share capital. Prior to this event, the acquirer held no shares or voting rights in the target company. Bliss GVS Pharma's total equity base stands at 10,63,30,472 shares, with a diluted capital base of 10,90,11,222 shares.
Original exchange filing (PDF)
More announcements from Bliss GVS Pharma Ltd
- Please find enclosed herewith the Intimation under Regulation 30 of the SEBI Listing Regulations. 路 06 Nov 2026
- We wish to inform you that Asterisk Lifesciences Ltd, UK, a wholly owned subsidiary of Bliss GVS Pharma Limited, has obtained marketing authorization from the Medicines & Healthcare products .... 路 04 Nov 2026
- Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 29 Oct 2026
- Please find enclosed herewith the outcome of Nomination and Remuneration Committee meeting held today i.e. on October 29, 2026, the members has granted 2,95,000 stock options under Bliss .... 路 29 Oct 2026
- Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026 路 29 Oct 2026
- Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026 路 29 Oct 2026
- Please find attached the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. 路 29 Oct 2026
- Bliss GVS Pharma Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 29 Oct 2026
